DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Angeles Investment Advisors LLC

Angeles Investment Advisors LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 10.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,300 shares of the medical device company’s stock after selling 640 shares during the period. Angeles Investment Advisors LLC’s holdings in DexCom were worth $355,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after buying an additional 136,282 shares in the last quarter. Blair William & Co. IL raised its stake in DexCom by 1.4% during the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after purchasing an additional 64,683 shares during the period. Legal & General Group Plc raised its stake in DexCom by 1.7% during the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after purchasing an additional 49,076 shares during the period. Massachusetts Financial Services Co. MA raised its stake in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after purchasing an additional 353,019 shares during the period. Finally, 1832 Asset Management L.P. raised its stake in DexCom by 1.1% during the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock worth $252,906,000 after purchasing an additional 20,400 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Trading Down 1.1 %

Shares of DexCom stock traded down $0.79 during mid-day trading on Wednesday, hitting $73.55. 215,418 shares of the stock were exchanged, compared to its average volume of 3,900,482. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market capitalization of $28.73 billion, a price-to-earnings ratio of 44.52, a price-to-earnings-growth ratio of 2.16 and a beta of 1.17. The company has a 50-day simple moving average of $69.68 and a 200 day simple moving average of $92.63. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Robert W. Baird boosted their price target on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Leerink Partners reduced their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Morgan Stanley reduced their price target on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a research note on Friday, July 26th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average target price of $104.59.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.